65,437 trials
Pain
Primary: Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 1 g IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10…
Tobacco Abstinence
Primary: Biochemically Confirmed Abstinence From Smoking — 10 participants
Skin Resurfacing · Wrinkle Reduction
Primary: Improvement in Fine Lines — 1.77 Scores on a scale
Nasolabial Folds
Primary: Treatment Difference in VAS (Perlane Side - Perlane-L Side) With Difference in VAS >= 10 mm — 95 Participants
Diabetes Mellitus
Primary: Average Number of Weekly Post-Prandial Blood Glucose Tests Performed by Subjects Using Either Basic or Advanced Meter Features — 7.1; 10.2 number of post-prandial tests…
Pancreatic Neoplasms
Primary: Overall Survival for the Intent to Treat Population — 5.2; 6.8 months — p=0.2
Myeloid Leukemia, Chronic
Primary: Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 — 45; 29; 75; 92 percentage of participants
Multiple Sclerosis
Primary: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in…
Device Replacement · Elective Replacement (ERI) · Device Advisory
Primary: Percentage of Subjects Experiencing a Complication During Generator Replacement Without a Planned Lead Revision or Addition (Straight-forward Device Replacment) or With…
Asthma
Primary: Integrated Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline) — 1.35; 1.16 Units on a scale
Breast Neoplasms
Primary: Percentage of Participants With Objective Response (OR)
Multiple Myeloma · Lymphoma, Non-Hodgkin
Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 4; 8; 12; 4 participants
BPH
Primary: Testosterone Area Below Baseline Interval — 21.0; 16.0; 54.6; 70.6 ng*days/mL
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 4; 20; 24; 2 participants
Neoplasm, Malignant
Primary: Number of Participants With Adverse Events — 6; 6; 0; 0 Participants